1. The efficacy of ascorbic acid in suboptimal responsive anemic hemodialysis patients receiving erythropoietin: a meta-analysis.
- Author
-
Einerson B, Chaiyakunapruk N, Kitiyakara C, Maphanta S, and Thamlikitkul V
- Subjects
- Adult, Female, Hemoglobins analysis, Humans, Injections, Intravenous, Iron metabolism, Iron therapeutic use, Iron Overload drug therapy, Kidney Failure, Chronic blood, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy, Male, Middle Aged, Randomized Controlled Trials as Topic, Anemia drug therapy, Antioxidants therapeutic use, Ascorbic Acid therapeutic use, Erythropoietin therapeutic use, Renal Dialysis
- Abstract
Background: To determine the impact of adjuvant ascorbic acid therapy on erythropoietin-hyporesponsive, anemic patients undergoing hemodialysis., Data Sources: The online databases of PubMed, Cochrane library, IPA, CINAHL, EMBASE, clinicaltrial.gov, WHO trial registry and PyschINFO were used., Study Selection: Studies comparing ascorbic acid to a control, with participants receiving erythropoietin and hemodialysis, and reported outcomes for hemoglobin or transferring saturation., Data Extraction: Two independent researchers reviewed titles and abstracts to determine relevance and extracted study design, dose, duration, baseline values, and outcomes., Data Synthesis: Five studies met all the criteria and were used for final analysis. The calculated weighted mean difference between hemoglobin in the ascorbic acid group versus the control group was 0.96 g/dL (95% CI, 0.78 to 1.14). The calculated weighted mean difference between transferrin saturation in the ascorbic acid treatment group versus the control was 8.26% (95% CI, 6.59 to 9.94)., Conclusion: Adjuvant ascorbic acid significantly raises hemoglobin levels in patients with erythropoietin hyporesponsiveness undergoing hemodialysis. The significant rise in transferrin saturation indicates that this positive effect on erythropoietin response may be due to increased iron utilization.
- Published
- 2011